Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals

Diagnostic Microbiology and Infectious Disease
M V VillegasColombian Nosocomial Resistance Study Group (See )

Abstract

Gram-negative pathogens harboring extended-spectrum beta-lactamases (ESBL) are widely prevalent in Latin America, but little is known about their prevalence in Colombia. A network of 8 tertiary care hospitals in Bogotá, Medellín, and Cali, Colombia, was formed in January 2002 to determine the prevalence of ESBL-producing Klebsiella pneumoniae and Escherichia coli. We characterized and established the molecular epidemiology of ESBLs from these hospitals. Data from 1074 E. coli and 394 K. pneumoniae isolates were obtained from hospital laboratories during 6 months. Isolates resistant to third-generation cephalosporins or aztreonam were sent to a central laboratory. The prevalence of strains with this phenotype was 32.6% in K. pneumoniae and 11.8% in E. coli from the intensive care units, with slightly lower percentages from wards. Although TEM and SHV enzymes were present, the dominant class was CTX-M. Molecular typing of chromosomal DNA showed that most strains were not clonal.

References

Nov 24, 1979·Nucleic Acids Research·H C Birnboim, J Doly
Oct 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G S ItokazuR A Weinstein
Apr 29, 1998·Diagnostic Microbiology and Infectious Disease·J EnaI Ruíz-López
Feb 18, 1999·JAMA : the Journal of the American Medical Association·J WienerR A Weinstein
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P L WinokurN Legakis
Sep 21, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E LautenbachN O Fishman
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·C DutourJ Sirot
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·Aroonwadee ChanawongPeter Michael Hawkey
May 11, 2002·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·A MavroidiL S Tzouvelekis
Jun 28, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R OdehJ P Quinn
Feb 4, 2003·The Journal of Antimicrobial Chemotherapy·I AlobwedeP M Hawkey
Feb 18, 2003·JAMA : the Journal of the American Medical Association·Melinda M NeuhauserJohn P Quinn
Jun 25, 2003·Antimicrobial Agents and Chemotherapy·E Smith MolandS Pottumarthy
Aug 26, 2003·Antimicrobial Agents and Chemotherapy·M QuinterosUNKNOWN Microbiology Study Group
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group

❮ Previous
Next ❯

Citations

Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group
Jun 9, 2012·BMC Research Notes·Rayo Morfin-OteroEduardo Rodriguez-Noriega
May 17, 2008·Diagnostic Microbiology and Infectious Disease·Kwan Soo KoNam Yong Lee
Jan 18, 2012·Tropical Medicine & International Health : TM & IH·Juliëtte A SeverinWil H Goessens
Sep 17, 2005·Diagnostic Microbiology and Infectious Disease·Yoichi HirakataUNKNOWN SENTRY Asia-Pacific Participants
Sep 1, 2012·Journal of Medical Microbiology·Ryuichi NakanoRyoichi Okamoto
Aug 13, 2009·Journal of Biomedicine & Biotechnology·King-Ting LimKwai-Lin Thong
Sep 12, 2012·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Pedro MartinezSalim Mattar
Aug 2, 2016·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Diana Yessenia Calva DelgadoAlessio Ausili
Apr 14, 2016·Antimicrobial Agents and Chemotherapy·Laura J RojasRobert A Bonomo
Apr 15, 2015·Beneficial Microbes·I SmidtR Mändar
Nov 20, 2012·Journal of Medical Microbiology·Kesavaram PadmavathySikhamani Rajasekaran
Apr 12, 2011·Journal of Food Protection·Neslihan GundoganEmel Yalcin
Sep 19, 2019·Biomédica : revista del Instituto Nacional de Salud·Carlos Andrés Vargas-AlzateJudy Natalia Jiménez-Quiceno
Sep 19, 2019·Biomédica : revista del Instituto Nacional de Salud·Ana Mercedes RadaMaria Virginia Villegas
Jul 22, 2021·JAC-antimicrobial Resistance·Mariana CastanheiraPatricia A Bradford
Aug 4, 2021·Microbial Biotechnology·Christian MoguetHervé Volland

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.